Chris Packard, Professor of Vascular Biochemistry at the University of Glasgow, UK, highlights the importance of PROMINENT trial data on triglyceride lowering to reduce cardiovascular risk and new insights into the role of ANGPTL3, 4 and 8 proteins and apoCIII in controlling triglyceride-rich lipoproteins levels.